ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone Marrow Transplant Meetings NEW YORK, NY - February 21, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) presented preclinical data showing ZIO-201, the active metabolite of ifosfamide, may be less likely to kill normal kidney cells
ZIOPHARM Presents ZIO-201 Preclinical Data at Bone Marrow Transplant Meetings NEW YORK, NY - February 17, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) presented preclinical data today at the 2006 Bone Marrow Transplant Meetings in Honolulu demonstrating that ZIO-201, the Company's proprietary
ZIOPHARM to Present at Arch Investment Conference NEW YORK, NY - February 15, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Arch Investment Conference on Thursday, February 23, 2006 at 11:30 a.m.
ZIOPHARM Receives Second ZIO-101 Patent Issuance NEW YORK, NY - February 9, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today a second organic arsenic case has been issued as U.S. Patent No. 6995188. The patent issue follows an announcement of a notice of allowance in mid-January.
ZIOPHARM Appoints Senior Vice President for Technical Operations NEW YORK, NY - January 19, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today the appointment of Barbara Wallner, Ph.D., as Senior Vice President, Technical Operations and Chief Technical Officer, reporting to Dick Bagley,
ZIOPHARM Receives Notice of Allowance on Key ZIO-101 Patent NEW YORK, NY - January 17, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today it received a notice of allowance from the U.S. Patent and Trademark Organization in a second organic arsenic case, its first organic arsenic case
ZIOPHARM Announces Appointment of Vice President for Regulatory Affairs NEW YORK, NY - January 09, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today the appointment of Robert Morgan, MS, JD, as Vice President of Regulatory Affairs and Quality, and Contract Counsel, reporting to Dick
ZIOPHARM Oncology Information Available through S&P Market Access Program NEW YORK, NY - January 06, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service